Ausgabe 1/2014
Inhalt (8 Artikel)
Editorial
Why Should Regulators Consider Using Patient Preferences in Benefit-risk Assessment?
Janine A. van Til, Maarten J. IJzerman
Review Article
Use of Proton Pump Inhibitors for the Provision of Stress Ulcer Prophylaxis: Clinical and Economic Consequences
Jeffrey F. Barletta, David A. Sclar
Review Article
Review of Models Used in Economic Analyses of New Oral Treatments for Type 2 Diabetes Mellitus
Carl V. Asche, Stephen E. Hippler, Dean T. Eurich
Systematic Review
Cost Effectiveness of the New Pneumococcal Vaccines: A Systematic Review of European Studies
Katelijne van de Vooren, Silvy Duranti, Alessandro Curto, Livio Garattini
Original Research Article
The Impact of Structural Uncertainty on Cost-Effectiveness Models for Adjuvant Endocrine Breast Cancer Treatments: the Need for Disease-Specific Model Standardization and Improved Guidance
Gerardus W. J. Frederix, Johan G. C. van Hasselt, Jan H. M. Schellens, Anke M. Hövels, Jan A. M. Raaijmakers, Alwin D. R. Huitema, Johan L. Severens
Original Research Article
Comparative and Cost Effectiveness of Treatment Modalities for Hepatocellular Carcinoma in SEER-Medicare
Fadia T. Shaya, Ian M. Breunig, Brian Seal, C. Daniel Mullins, Viktor V. Chirikov, Nader Hanna
Original Research Article
The Value of a QALY: Individual Willingness to Pay for Health Gains Under Risk
Ana Bobinac, Job van Exel, Frans F. H. Rutten, Werner B. F. Brouwer
Original Research Article
Treating Idiopathic Pulmonary Fibrosis with the Addition of Co-Trimoxazole: An Economic Evaluation Alongside a Randomised Controlled Trial
Edward C. F. Wilson, Ludmila Shulgina, Anthony P. Cahn, Edwin R. Chilvers, Helen Parfrey, Allan B. Clark, Orion P. Twentyman, Andrew M. Wilson